Navigation Links
Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Date:3/26/2013

CHARLOTTESVILLE, Virginia und CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ --

DART Therapeutics Inc., ein innovatives Biotechnologie-Unternehmen neuester Art, das sich auf die Entwicklung von Therapien für die Duchenne-Muskeldystrophie (DMD) konzentriert, und Biovista, ein führender Anbieter für die systematische Neupositionierung von Medikamenten, gaben heute bekannt, dass sie eine Forschungskooperation eingegangen sind, um neuartige Kandidaten für die Neupositionierung von Medikamenten für DMD zu identifizieren und zu entwickeln, wobei die Biovista-Technologie "Clinical Outcome Search Space" (COSS) ™ genutzt werden soll. Gemäß der Vereinbarung wird Biovista neuartige Kandidaten für die Neupositionierung identifizieren und die Firma DART Therapeutics wird die Möglichkeit haben, eine bestimmte Anzahl für die weitere Entwicklung auszuwählen. Die Bedingungen der Vereinbarung umfassen eine Vorauszahlung und nachgeschaltete erfolgsabhängige Zahlungen.

"Die Neupositionierung von Medikamenten ist ein wichtiger Ansatz in unserer Gesamtstrategie zur möglichst effizienten Identifikation neuartiger Behandlungsmethoden für DMD", sagte Gene Williams , Chief Executive Officer von DART Therapeutics. "Biovista und die COSS-Technologie sind führend in der systematischen Neupositionierung und gewährleisten uns die breitestmögliche Abdeckung aller Möglichkeiten der Neupositionierung, die wirklich starke Auswirkungen auf Patienten und ihre Familien haben können, die auf eine Behandlung für DMD warten."

"Das Unternehmen DART Therapeutics steht für ein einzigartiges Modell, das den Entwicklungsarm einer großen Interessengruppe von Patienten darstellt. Die Führungsrolle des Unternehmens bei DMD ist eine ausgezeichnete Ergänzung zu unseren eigenen F
'/>"/>

SOURCE Biovista, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  US-Australian drug discovery company, Novogen Limited (ASX: ... comprehensive scientific review has identified high value opportunities ... unmet patient need. Novogen is moving as quickly ... to entering into Phase 1 clinical trials with ... Executive Officer, Iain Ross , said that ...
(Date:8/31/2015)... Aug. 31, 2015 LabStyle Innovations Corp. ... Solution, today announced it recently closed a round ... be used to support the global rollout and ... mobile, cloud-based, diabetes management solution that includes novel ... blood glucose monitoring device, and for working capital ...
(Date:8/31/2015)... ... 31, 2015 , ... The Food Processing Suppliers Association's PROCESS ... equipment manufacturers and leaders in the field of academia. , METTLER TOLEDO ... manufacturers of bakery and snacks; beverages; dairy; meat, poultry and seafood; and prepared ...
(Date:8/30/2015)... CHERTSEY , England , August ... Kampagne beendet die 51-jährige Wartezeit   einer Frau   ... und Frauen im Alter von 7-90   ... Programm soll 1200 Frauen behandeln und ...     , Astellas gab heute ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... (Amex:,SGN) announced earlier today that breaking news will ... regarding the law firm of Vianale & Vianale, ... a life sciences company focused on the monitoring,detection ... Signalife uses its patented signal technology to design ...
... SAN DIEGO, Sept. 2 Halozyme Therapeutics,Inc. ... developing and,commercializing products targeting the extracellular matrix, ... Vice President,Research, Michael J. LaBarre, PhD, Vice ... President, Legal., "Halozyme is committed to ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that ... the Company is initiating a U.S.,Phase 2 ... in,combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal,Investigator is Dr. ...
Cached Biology Technology:Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 3Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 4/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 2/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 3/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 4
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Louis sheds light on one of the most important events ... years ago. No would-be colonizer could have survived on ... major threat for organisms accustomed to soaking in water. ... drying out might be provided by bryophytes, a group that ...
... of Minnesota have found that the hydrodynamic environment of fish ... available on the Journal of Experimental Biology Web ... for Earth-surface Dynamics. Catch a glimpse of a fish,s ... is. Tuna and mackerel look as if they should outpace ...
... the progression of advanced renal cell carcinoma (RCC), a form ... a new study published in the Journal of Clinical ... disease, but the outlook for patients has improved in the ... multiple pathways within cancer cells," study author Dr. Cora N. ...
Cached Biology News:Moss helps chart the conquest of land by plants 2Moss helps chart the conquest of land by plants 3Moss helps chart the conquest of land by plants 4Research finds water movements can shape fish evolution 2Promising results shown for kidney cancer drug 2